Invivyd Reports Positive Phase 3 Results for VYD2311 COVID-19 Antibody Study

Key Facts

1Invivyd announced positive topline Phase 3 data from the LIBERTY study showing VYD2311 safety and tolerability were superior to mRNA-based COVID-19 vaccines.

Invivyd announced positive topline Phase 3 data from the LIBERTY study showing VYD2311 safety and tolerability were superior to mRNA-based COVID-19 vaccines. The company said in a statement via GlobeNewswire that the results for its investigational COVID-directed monoclonal antibody reached statistical and clinical significance.

The study evaluated the safety and potential immunologic interference of VYD2311 when administered alone or co-administered with mRNA vaccines. Regarding market performance, IVVD closed at $0.95 on September 28, 2026, having traded between a day low of $0.94 and a high of $1.01 during that session.